Price movement over the last 24 hours
Abeona Therapeutics Inc vs Iris Energy Limited — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Iris Energy Limited trades at $41.95 (market cap $14.23B). The key difference: Iris Energy Limited is far larger — about 38.1× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Iris Energy Limited nearer its low. Which is the better fit depends on your goals.
| ABEO | IREN | |
|---|---|---|
Market Cap | $373.32M | $14.23B |
Sector | Health | Energy |
52-Week High | $7.23 | $76.41 |
52-Week Low | $4.17 | $15.40 |
Enterprise Value | $228.22M | $15.98B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
IREN stock trades at $43.91, up 13.11% today amid speculation about a potential $22 billion Anthropic deal. The technical picture remains bearish despite the rally, with the stock missing earnings expectations for three consecutive quarters. Revenue growth appears strong with 2026 projections showing $757 million, though profitability metrics show negative ROE and ROA. Analyst consensus remains bullish with a $79.11 price target despite recent volatility.
The investment case hinges on IREN's transition from Bitcoin mining to AI infrastructure, with significant capacity expansion funded by substantial financing activities. Key risks include execution challenges in scaling operations, competitive pressure from established cloud providers, and reliance on speculative contract wins. The current valuation at 57x P/E appears stretched given negative returns on equity.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →